Literature DB >> 16457151

Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.

Seock-Ah Im1, Kyung Eun Lee, Eunmi Nam, Do Yeun Kim, Joo-Ho Lee, Ho-Seong Han, Ju-Young Seoh, Hae-Young Park, Min-Sun Cho, Woon Sup Han, Soon Nam Lee.   

Abstract

AIMS AND
BACKGROUND: The HER2 gene encodes a 185-kd transmembrane glycoprotein receptor (p185(HER2)) that has partial homology with the epidermal growth factor receptor and shares intrinsic tyrosine kinase activity. The phosphatase and tensin homolog mutated on chromosome ten (PTEN) gene product is a protein tyrosine phosphatase that participates in modulating the phosphoinositide 3-kinase pathway which has antagonizing activity to protein tyrosine kinase. The authors investigated the correlation between clinicopathologic variables including survival and the overexpression of the p185(HER2) with loss of PTEN expression in gastric adenocarcinoma patients.
METHODS: The protein expression of p185(HER2) and PTEN was examined by immunohistochemical stain in paraffin-embedded tissues of 94 (M:F, 52:42) gastric adenocarcinoma patients by using monoclonal antibody, and the results were related to clinicopathological variables and survival.
RESULTS: p185(HER2) overexpression correlated positively with lymph node metastasis, distant metastasis, AJCC classification, higher relapse rate. Patients with overexpression of p185(HER2) were found to have significantly lower disease-free survival (P = 0.003) and overall survival (P = 0.0004). Loss of PTEN expression correlated positively with depth of invasion (T stage) and was more frequent in the advanced stage. The patient group with p185(HER2) overexpression and loss of PTEN expression showed significantly shorter disease-free and overall survival (P = 0.03, P = 0.01) than the other groups.
CONCLUSIONS: Our observations suggest potential prognostic significance of p185(HER2) overexpression with PTEN loss in gastric adenocarcinoma patients. This opens up the possibility of considering p185(HER2)and PTEN as a therapeutic target in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16457151     DOI: 10.1177/030089160509100612

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  16 in total

1.  PTEN gene is infrequently hypermethylated in human esophageal squamous cell carcinoma.

Authors:  Zhenguo Sun; Na Ji; Mingming Bi; Shuai Wang; Xiangyan Liu; Zhou Wang
Journal:  Tumour Biol       Date:  2015-02-28

Review 2.  Targeted therapies for gastric cancer: current status.

Authors:  Jaclyn Yoong; Michael Michael; Trevor Leong
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 3.  Targeting receptor tyrosine kinases in gastric cancer.

Authors:  Asahiro Morishita; Jian Gong; Tsutomu Masaki
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

Authors:  Hilda Wong; Thomas Yau
Journal:  Oncologist       Date:  2012-02-14

Review 5.  Targeting the human EGFR family in esophagogastric cancer.

Authors:  Alicia Okines; David Cunningham; Ian Chau
Journal:  Nat Rev Clin Oncol       Date:  2011-04-05       Impact factor: 66.675

Review 6.  Molecular markers for gastric adenocarcinoma: an update.

Authors:  Casandra Anderson; Amar Nijagal; Joseph Kim
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 7.  Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

Authors:  Takayasu Kurata; Junji Tsurutani; Yasuhito Fujisaka; Wataru Okamoto; Hidetoshi Hayashi; Hisato Kawakami; Eisei Shin; Nobuya Hayashi; Kazuhiko Nakagawa
Journal:  Invest New Drugs       Date:  2014-05-31       Impact factor: 3.850

9.  The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.

Authors:  Stuti Shroff; Michael J Overman; Asif Rashid; Rachna T Shroff; Hua Wang; Deyali Chatterjee; Matthew H Katz; Jeffrey E Lee; Robert A Wolff; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Arch Pathol Lab Med       Date:  2013-11       Impact factor: 5.534

10.  Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer.

Authors:  Fen Yun; Yongfeng Jia; Xiuxia Li; Li Yuan; Qinnuan Sun; Huiling Yu; Lin Shi; Hongwei Yuan
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.